Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.

Health Care Professionals Log In

References

  1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
  2. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2006. Washington, DC: American Psychiatric Association; 2006:771-788.
  3. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-1180.
  4. Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38:249-257.
  5. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text rev. Washington, DC: American Psychiatric Association; 2000:372.
  6. Data on file, Wyeth Pharmaceuticals Inc.
  7. EFFEXOR XR® (venlafaxine HCl) Extended-Release and EFFEXOR® Immediate-Release Prescribing Information. Wyeth Pharmaceuticals Inc.
  8. Ferguson JM, Khan A, Mangano R, et al. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry. 2007;68:58-68.
  9. Montgomery SA, Sheehan DV, Meoni P, et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002;36:209-217.
  10. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19:387-396.
  11. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.

Phases of Treatment Map References

  1. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52:28-34.
  2. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 2nd ed. Arlington, VA: American Psychiatric Association; 2000.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Rev. Washington, DC: American Psychiatric Association; 2000.
  4. Paykel ES, Cooper RZ, Hayhurst JK, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-1180.
  5. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
  6. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157:1501-1504.
  7. Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38:249-257.
  8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
  9. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000-1006.
  10. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157:229-233.
258973-01